[12] Patent
[11] Patent No.:GC0007507  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/125426
Date of the Decision to Grant the Patent:04/Apr/2018

[21] Application No.:GCC/P/2005/5453

[22] Filing Date:30/11/2005

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
3/12/2004
60/633.132

[72] Inventors:1- KEVIN M. BELYK،2- VINCENZO SUMMA،3- HENRY G. MORRISON،4- PHILIP JONES

[73] Owners:1- MSD ITALIA S.r.I, Via Vitorchinao 151, 00189, Rome, Italy،2- MERCK & CO., INC., 126 East Lincoln Avenue, New, 07065, Rahway, USA

[74] Agent: Suleiman I. Al-Ammar Law Office

  

 

  

[51]IPC:
Int. Cl.7: A61K 31/513; A61P 31/18; C07D 413/12

[56] Cited Documents:

-WO 03/035077 A (ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE p. ANGELETTI SPA; CRESCENZ) 01 May 2003  
Examiner: PH. Mohammad S. AlMousa

[54] POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR
[57] Abstract: Potassium salts of Compound A and methods for their preparation are disclosed, wherein Compound A is of formula: Compound A.Compound A is an HIV integrase inhibitor useful for treating or prophylaxis of HIV infection, for delaying the onset of AIDS, and for treating or prophylaxis of AIDS.
No. of claims: 10     No. of figures: 4


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.